after treatment differences in fat infiltration scores (p>0.05). (Table1). Correlation analysis found that serum Dkk-1 concentration before treatment was significantly correlated with spinal bone marrow edema scores (P<0.01). The differences in serum Dkk-1 levels significantly correlate with differences in spinal MRI bone marrow edema scores after treatment (P<0.05). (Figure 1 and 2 Background: The prevalence of paradoxical psoriasis developed with biological use is already studied. However, none of these studies discriminate between psoriasis vulgaris (PV) and palmoplantar pustulosis (PPP), while these might be different entities (1). The prevalence in general population is 2-4% for PV and 0.01-0.05% for PPP (1-3). Moreover, most reports in the literature imply only a role for anti-Tumor necrosis factors (anti-TNF), although, a few cases described paradoxical psoriasis in patients treated with biologicals other than anti-TNF. Objectives: To study the prevalence and incidence density of paradoxical psoriasis and palmoplantar pustulosis in patients with rheumatoid arthritis (RA) and ankylosing spondylitis (AS) treated with biological therapy. Second to investigate differences between paradoxical psoriasis and palmoplantar pustulosis. Methods: Data were collected from the observational cohorts of AS and RA patients. 1499 consecutive patients were included for calculating prevalence and incidence density. Incidence density is calculated per 1000 person years. For calculating differences, only biological naïve patients (n=830) were included. Kaplan Meier curve was used to show the difference in time in onset. Results: In all, 13 cases of PPP and 16 cases of PV were observed in both the RA as AS cohorts. In AS patients 1.73% developed PPP and 1.38% PV. In RA patients respectively 0.66% and 0.99%. The incidence density of PPP in RA was 2.1 (95% CI 0.7-3.6), for PV 3.2 (95% CI 1.4-5.0). In AS, 4.7 (95% CI 0.6-8.8) for PPP and 3.7 (95% CI 2.3-12.7) for PV. Although not statistically significant, PPP was more prevalent in adalimumab (0.94%) compared to etanercept (0.34%). In contrast, PV occurs in 0.53% in adalimumab and 0.92% in etanercept treated patients. PPP was only observed in anti-TNF, PV was also observed in 1 patient treated with tocilizumab and 1 with abatacept. A difference was observed in the time to event, with a median of 6 months (IQR 4-16 months) for PPP and 50 months (IQR 11-67 months) for PV; p=0.003 (figure 1). Discontinuation of biological treatment was indicated in 80% of the PPP patients and 18.2% PV patients.
Conclusions:
Our findings show that biological therapy in patients with RA or AS is associated with a 13 to 35 fold increase in prevalence of PPP. While the prevalence of biological-associated PV is lower than the prevalence of PV in the general population. In this study PV and PPP are different from each other regarding prevalence, time to onset and consequences for biological treatment, and therefore should be considered as separate entities. Conclusions: IL17 gene expression in synovial membrane from patients with psoriatic arthritis was higher than in seronegative undetermined arthritis, osteoarthritis and ankylosing spondylitis patients, correlating positively with DKK1 and negatively with bone morphogenetic proteins 2 and 4. In addition, TGF-beta in synovial tissue, necessary for the activation of Th17 cells, was higher in patients with psoriatic arthritis, in relation to IL17 and DKK1 increased. Serum TGF beta 1 levels were also higher in patients with erosive disease. 
